KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Astrazeneca (AZN) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Astrazeneca (AZN) over the last 16 years, with Q4 2025 value amounting to -$484.0 million.

  • Astrazeneca's Interest Expenses fell 1282.05% to -$484.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.7 billion, marking a year-over-year increase of 206.66%. This contributed to the annual value of -$1.7 billion for FY2025, which is 275.55% up from last year.
  • Astrazeneca's Interest Expenses amounted to -$484.0 million in Q4 2025, which was down 1282.05% from -$434.0 million recorded in Q3 2025.
  • Astrazeneca's 5-year Interest Expenses high stood at $27.0 million for Q1 2021, and its period low was -$484.0 million during Q4 2025.
  • Over the past 5 years, Astrazeneca's median Interest Expenses value was -$378.5 million (recorded in 2023), while the average stood at -$369.8 million.
  • As far as peak fluctuations go, Astrazeneca's Interest Expenses skyrocketed by 10813.25% in 2021, and later crashed by 134444.44% in 2022.
  • Over the past 5 years, Astrazeneca's Interest Expenses (Quarter) stood at -$336.0 million in 2021, then fell by 7.14% to -$360.0 million in 2022, then fell by 23.61% to -$445.0 million in 2023, then grew by 3.6% to -$429.0 million in 2024, then fell by 12.82% to -$484.0 million in 2025.
  • Its last three reported values are -$484.0 million in Q4 2025, -$434.0 million for Q3 2025, and -$439.0 million during Q2 2025.